Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Patient-derived organoids (PDOs) model treatment response of metastatic gastrointestinal cancers.

ABSTRACT: Patient-derived organoids (PDOs) model treatment response of metastatic gastrointestinal cancers.

PROVIDER: PRJNA427119 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6409340_1.fastq.gz	Fastqsanger.gz
	SRR6409340_2.fastq.gz	Fastqsanger.gz
	SRR6409341_1.fastq.gz	Fastqsanger.gz
	SRR6409341_2.fastq.gz	Fastqsanger.gz
	SRR6409342_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

Culture media composition influences patient-derived organoids ability to predict therapeutic response in gastrointestinal cancers

Project description:In this study, we have generated patient-derived organoids (PDOs) from primary and metastatic lesions of gastrointestinal cancers, including pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, and cholangiocarcinoma and evaluated their ability to predict donor tumor drug response. Specifically, we examined individual PDO responses to therapeutic agents with the observed clinical responses of donor patients to the same treatments and demonstrated an approximately 80% concordance rate. Importantly, we found a profound influence of culture media in PDOs phenotypes, we observed a significant difference in response to common PDAC chemotherapies, distinct morphologies, and transcriptomes between media in the same PDOs. These studies demonstrate the important role of culture media when using PDOs to inform patient care and predict response across a spectrum of GI cancers. We compared transcriptome data from pancreatic ductal adenocarcinoma patient-derived organoids in two media (WNT and PaTOM).

2022-10-12 | GSE212014 | GEO

Patient-derived organoids (PDOs) model treatment response of metastatic gastrointestinal cancers.

Project description:We report RNAseq data from subsequent passages of five organoid cultures.

2017-12-22 | GSE108391 | GEO

RNA sequencing of metastatic breast patient derived organoids (PDOs) treated with control and CAF-conditioned media, in the presence and absence of Fulvestrant

Project description:To gain insight into the gene expression profile of breast patient derived organoids (PDOs) under endocrine therapy, and how cancer associated fibroblasts (CAFs) might influence gene expression and stimulate resistance, we performed RNA sequencing on three of the metastatic PDOs treated with control media and CAF-conditioned media, in the presence and absence of Fulvestrant (4-day treatment). These data revealed that Fulvestrant significantly suppressed the ER signature in the PDOs, suggesting that the ER-pathway is still active in these tumors although the patients had relapsed on ER-targeting agents (Tamoxifen, Letrozole).

2023-06-27 | GSE216540 | GEO

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Project description:Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs from metastatic, heavily pretreated colorectal and gastroesophageal cancer patients recruited in phase 1/2 clinical trials. Phenotypic and genotypic profiling of PDOs showed a high degree of similarity to the original patient tumors. Molecular profiling of tumor organoids was matched to drug-screening results, suggesting that PDOs could complement existing approaches in defining cancer vulnerabilities and improving treatment responses. We compared responses to anticancer agents ex vivo in organoids and PDO-based orthotopic mouse tumor xenograft models with the responses of the patients in clinical trials. Our data suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.

| S-EPMC6112415 | biostudies-literature

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers (targeted and whole-genome sequencing)

Project description:Patient-derived organoids (PDOs) have recently emerged as robust pre-clinical models, however, their potential to predict patient clinical outcomes remain unclear. We report a living biobank of PDOs from metastatic, heavily-pretreated colorectal and gastroesophageal cancer patients recruited in phase I/II clinical trials. Phenotypic and genotypic profiling of PDOs showed a high-degree of similarity to the original patient tumor. Molecular profiling of tumor organoids was matched to drug screening results, suggesting PDOs could complement existing approaches in defining cancer vulnerabilities and improving treatment responses. We compared ex vivo organoid responses to anticancer agents, and PDO-based orthotopic mouse tumor xenograft models to the response of the patient in clinical trials. Our data suggest that PDOs can recapitulate patient responses in the clinic, and have the potential to be implemented in personalized medicine programs.

| EGAS00001002784 | EGA

Cancer gene discovery in mouse gastrointestinal cancers

Project description:Cancer gene discovery in mouse gastrointestinal cancers

| PRJEB2471 | ENA

Expression data from CRC patient-derived organoids

Project description:Colorectal cancer (CRC) is a commonly occurring cancer worldwide. Metastasis and recurrence are the major causes of cancer-related death. CRC progression is a multistep process, and extensive efforts have been made to identify the genomic and transcriptomic alterations that occur during this process. However, whether primary tumors and metastatic lesions possess distinct biological features remains unclear. We established 74 patient-derived organoids (PDOs) from primary tumors and patient-matched metastatic and recurrent lesions.

2021-04-01 | GSE128213 | GEO

Proteomics profiling in primary tumors of metastatic and non-metastatic breast cancers

Project description:Analysis of different proteomics profile in primary tumors of metastatic and non-metastatic breast cancers.

2023-03-09 | PXD037288 | Pride

To study the function of KLF5 in squamous cancers and gastrointestinal cancers

Project description:To study the function of KLF5 in squamous cancers and gastrointestinal cancers

| PRJNA622284 | ENA

Culture media composition influences patient-derived organoids ability to predict therapeutic response in gastrointestinal cancers

Project description:Culture media composition influences patient-derived organoids ability to predict therapeutic response in gastrointestinal cancers

| PRJNA873279 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data